PCI Biotech: Presentation of fimaChem Phase I data in bile duct cancer at The International Liver Congress 2017

Oslo, Norway, April 21, 2017 PCI Biotech (OSE:PCIB), a clinical-stage company
developing innovative therapeutics that address significant unmet medical needs,
today announced that a poster of the fimaChem technology will be presented at
the International Liver Congress 2017 - the annual meeting of the European
Association for the Study of the Liver (EASL).

The event is taking place in Amsterdam, the Netherlands, from 19 to 23 April
2017, and Dr. Richard Sturgess, Coordinating Investigator of PCI Biotech's phase
I study in inoperable bile duct cancer, will present the fimaChem poster on 21
April 2017.  The poster is named "Phase I study with Photochemical
Internalisation (PCI) - A novel technology for treatment of perihilar
cholangiocarcinoma" and includes a brief technology and method background and
results from the recent fimaChem phase I study.

The results include an update on interim average overall survival data of 14.5
months per end March 2017, with 25% of the patients still being alive. Patients
are on PCI Biotech's phase I study in inoperable extrahepatic bile duct cancer
for six months, and thereafter followed for survival only.

The median overall survival (OS) in the studies that established gemcitabine and
cisplatin as standard treatment in cholangiocarcinoma (CCA) was 11.7 and 11.2
months respectively (Valle et al. NEJM (2010) 362:1273-81 and Okusaka et al. BJC
(2010) 103:469-74). These results may however not be directly comparable to the
data in the fimaChem phase I study, as these studies include a wide range of
different inoperable CCA patients, while the fimaChem phase I study focuses on
inoperable perihilar CCA patients.

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies for the treatment of cancer through its
innovative photochemical internalisation (PCI) technology platform.  PCI is
applied to three distinct anticancer paradigms: fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction
technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics
delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company's lead fimaChem programme consists of a clinical Phase I/II clinical
study in bile duct cancer, an orphan indication with a high unmet need and
without approved products. fimaVacc applies a unique mode of action to enhance
the essential cytotoxic effect of therapeutic cancer vaccines, which works in
synergy with several other state-of-the-art vaccination technologies. fimaNAc
utilises the endosomal release to provide intracellular delivery of nucleic
acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.
www.pcibiotech.com
Per Walday, CEO, pw@pcibiotech.com , Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section
5 -12 of the Norwegian Securities Trading Act.